McLaren Teams Up With AbbVie Before Formula 1 United States GP At COTA

As Formula 1 arrives in Austin, Texas for this weekend’s United States Grand Prix at COTA, McLaren has announced a partnership to help provide aid to those who live with immune-mediated disease.

McLaren’s new partnership is with global biopharmaceutical company AbbVie on October 20. AbbVie will join the McLaren Mastercard Formula 1 Team as an Official Pharmaceutical Partner, starting at the United States Grand Prix.

The campaign will officially launch at the 2026 Formula 1 United States Grand Prix in Austin and continue into the 2027 Formula 1 season.

Details About The McLaren Partnership With AbbVie

The new partnership will launch AbbVie Race to Innovate, a campaign connecting McLaren’s performance on the track with support for people living with immune-mediated diseases. Through Race to Innovate, AbbVie will donate $10,000 for every 10 Constructors’ Championship points earned by McLaren, reflecting the approximately 10 percent of people worldwide affected by autoimmune diseases.

Donations will support patient advocacy organizations around the world that provide education, resources and support.

“We’re proud to welcome AbbVie to McLaren Racing at such an exciting moment for our team, ahead of the United States Grand Prix,” said Matt Dennington, Co-Chief Commercial Officer, McLaren Racing. “This partnership brings together two organizations that share a pursuit of progress, whether that’s pushing the limits of performance on track or advancing life-changing science off it. We’re looking forward to working with AbbVie to tell powerful stories about what it takes to drive progress, and to showcase the people and ideas behind it.”

The partnership connects the industries of high-performance motorsport and cutting-edge science. McLaren Racing’s legacy in motorsport and AbbVie’s leadership in developing innovative medicines and solutions reflect a shared ambition to challenge convention, push the boundaries and drive meaningful impact both on and beyond the track.

How McLaren And AbbVie Completment Each Other’s Mission

Although operating in different industries, both bring expert teams together to solve complex challenges and use precision and data to continually learn, refine and make improvements.

“AbbVie and McLaren may operate in different industries, but both are driven by a mindset of continuous improvement and shared determination to solve complex challenges,” said Tracie Haas, Senior Vice President, Corporate Affairs, AbbVie. “As a leader in immunology for nearly three decades, AbbVie is pressing forward to drive innovation for patients. Through Race to Innovate, we’re proud to bring that commitment to a global stage with McLaren, turning every 10 points scored on the track into support for people living with immune-mediated diseases and the organizations that serve them.”

AbbVie also has a strong relationship with Major League Baseball. AbbVie donates $20 for every MLB strikeout (capped at $1 million annually) to support Stand Up To Cancer.

For nearly 30 years, AbbVie has helped advance innovation in immunology, delivering treatment options to people living with immune-mediated diseases, while McLaren Racing continues to push the boundaries of performance through engineering excellence, innovation and teamwork. Together, AbbVie and McLaren Racing will bring to life the stories behind innovation, celebrating the breakthroughs, dedication and human ingenuity required to drive progress in both medicine and motorsport.

Building on the program’s inaugural year, AbbVie will continue donating for the full 2027 season while storytelling and fan engagement efforts will further highlight the shared pursuit of progress at the heart of the partnership.

AbbVie’s pursuit is to redefine the standard of care for patients living with immune-mediated conditions, with the goal of helping them live a life free from the limitations of their disease. AbbVie has led and helped shape the field of immunology through groundbreaking science and trusted medicines. Building on deep expertise across gastroenterology, rheumatology and dermatology, and other areas of high unmet need, AbbVie invests in a broad and differentiated pipeline – spanning innovative modalities, novel mechanisms of action and next-generation approaches designed to conquer the complex biology underlying immune-mediated disease.

More than one million patients worldwide are treated with AbbVie’s immunology medicines, approved in more than 175 countries across 20-plus immune-mediated diseases that impact adult and pediatric populations.

As the company works to strengthen its legacy and drive the next wave of innovation, AbbVie remains focused on delivering meaningful progress for patients and expanding access to its medicines.

AbbVie is located in North Chicago, Illinois, which makes the second of three Formula 1 World Championship visits to the United States an appropriate plate to kick off its relationship with McLaren.

This article was originally published on Forbes.com